SeekingAlpha · Sep 13, 2026
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here
Xenonâs Phase 3 azetukalner cut focal seizures by 53%, and FDA filing nears. Click for more on XENE stock.
XE
NASDAQ · XENE
Xenon Pharmaceuticals Inc.
Healthcare · Biotechnology
$56.76
Up+$0.48 (+0.85%)
Updated Sep 17, 2026, 11:24 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.37B
- P/E ratio
- -12.39
- Dividend yield
- 0.00%
- 52-week range
- $35.66 – $72.66
- Volume
- 723.67K
- Avg. volume
- 790.48K
Price performance
XENE price history
1M range · 20 trading sessions · Daily adjusted prices
XENE closed at $56.76 after 20 trading sessions, down 8.92% for the selected period.
- Last close
- $56.76
- Period change
- -8.92%
- Period low
- $56.28
- Period high
- $63.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $56.67 | $57.875 | $56.40 | $56.76 | 723.67K |
| Sep 15, 2026 | $58.13 | $58.13 | $56.17 | $56.28 | 587.02K |
| Sep 14, 2026 | $59.36 | $59.60 | $58.00 | $58.19 | 408.95K |
| Sep 11, 2026 | $60.00 | $60.00 | $58.53 | $58.65 | 466.75K |
| Sep 10, 2026 | $58.74 | $59.395 | $58.00 | $58.80 | 798.78K |
| Sep 9, 2026 | $59.04 | $59.81 | $58.53 | $58.98 | 489.45K |
| Sep 8, 2026 | $58.95 | $60.36 | $58.27 | $59.55 | 608.51K |
| Sep 4, 2026 | $60.02 | $60.57 | $59.43 | $59.75 | 459.23K |
| Sep 3, 2026 | $60.19 | $60.69 | $59.61 | $60.40 | 471.7K |
| Sep 2, 2026 | $60.56 | $61.75 | $59.68 | $60.16 | 637.2K |
| Sep 1, 2026 | $60.48 | $61.155 | $59.54 | $60.00 | 418.79K |
| Aug 31, 2026 | $59.84 | $60.81 | $59.22 | $60.22 | 752.7K |
| Aug 28, 2026 | $61.31 | $61.62 | $59.81 | $59.99 | 587.93K |
| Aug 27, 2026 | $63.13 | $63.775 | $61.85 | $61.93 | 586.97K |
| Aug 26, 2026 | $60.42 | $64.81 | $59.26 | $63.79 | 1.3M |
| Aug 25, 2026 | $61.01 | $61.67 | $60.26 | $60.42 | 418.01K |
| Aug 24, 2026 | $60.77 | $61.045 | $60.00 | $60.56 | 628.83K |
| Aug 21, 2026 | $60.45 | $61.57 | $59.7257 | $60.77 | 792.93K |
| Aug 20, 2026 | $61.41 | $62.51 | $59.27 | $59.73 | 627.24K |
| Aug 19, 2026 | $64.71 | $64.93 | $62.18 | $62.32 | 558.96K |
Latest XENE news
The latest Smart Investors Daily articles mentioning XENE.
Stock researchCompany · Overview
XENE research
Overview
Company profile and research snapshot.
Company profile
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $52.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| May 27, 2026 | JP Morgan | Overweight | — |
| May 12, 2026 | JP Morgan | Overweight | — |
| May 8, 2026 | Needham | Buy | — |
| May 8, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care
On August 26, Xenon Pharmaceuticals (NASDAQ:XENE) announced that it will deliver six data presentations at the 16th European Epilepsy Congress in Athens, Greece, running September 5 through 9. The headline slot is an oral presentation of topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, alongside two posters covering patients […]
Yahoo · Sep 3, 2026
Xenon to Present at Wells Fargo Healthcare Conference
VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: Wells Fargo Healthcare Conference, Boston, MAFireside Chat: Wednesday, September 9, 11:00–11:30 am ET Details about the presentation, inc
Yahoo · Aug 31, 2026
BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem
OTTAWA, Ontario, August 31, 2026--BIOTECanada, the national industry association representing Canada’s biotechnology sector, is pleased to announce the winners of the 2026 Gold Leaf Awards, recognizing outstanding leadership, innovation and impact across Canadian biotech.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
